Compare ResMed Inc. (RMD) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Toyota Motor Corp — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Toyota Motor Corp trades at $184.98 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 6.8× ResMed Inc.'s market cap, and Toyota Motor Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Toyota Motor Corp for 116 Days on average.
| RMD | TM | |
|---|---|---|
Market Cap | $31.89B | $217.38B |
Volume | 618,314 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $277.88 | $248.29 |
52-Week Low | $182.82 | $166.50 |
Typical Hold Time | 51 Days | 116 Days |
Enterprise Value | $31.24B | $410.96B |
Dividend Yield | 1.16% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Toyota Motor trades at $184.84, up 1.06% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while delivering consistent earnings beats. Recent U.S. sales growth and electrification progress contrast with China market challenges and production disruptions from Thailand floods.
Toyota presents a value opportunity with solid profitability and market share gains, though technical weakness and regional sales pressures warrant caution. The company's electrification investments and strong U.S. position support long-term growth, while currency risks and competitive pressures remain key monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
